These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25775418)

  • 1. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.
    Ohanian M; Kantarjian H; Guy D; Thomas D; Jabbour E; O'Brien S
    Expert Opin Biol Ther; 2015 Apr; 15(4):601-11. PubMed ID: 25775418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
    Thota S; Advani A
    Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotuzumab Ozogamicin: First Pediatric Approval.
    Dhillon S
    Paediatr Drugs; 2024 Jul; 26(4):459-467. PubMed ID: 38780741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
    Choudhry A; O'Brien SM
    Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B; Gerber HP; Sapra P
    Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
    Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
    BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
    Wynne J; Wright D; Stock W
    Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Garrett M; Ruiz-Garcia A; Parivar K; Hee B; Boni J
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):211-222. PubMed ID: 30859374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
    Torrent A; Morgades M; García-Calduch O; de Llano MPQ; Montesinos P; Navarro I; Hernández-Rivas JM; Bárez-García A; González-Campos J; Oiartzabal I; Valero M; Cervera M; Zudaire T; Albors-Ferreiro M; López-Godino O; Gil-Cortés C; Villalón L; Saldaña R; Ribera JM
    Eur J Haematol; 2023 Sep; 111(3):485-490. PubMed ID: 37381686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotuzumab Ozogamicin: First Global Approval.
    Lamb YN
    Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
    George B; Kantarjian H; Jabbour E; Jain N
    Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
    Ogura M; Tobinai K; Hatake K; Davies A; Crump M; Ananthakrishnan R; Ishibashi T; Paccagnella ML; Boni J; Vandendries E; MacDonald D
    Clin Cancer Res; 2016 Oct; 22(19):4807-4816. PubMed ID: 27154915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD
    Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Ogura M; Hatake K; Ando K; Tobinai K; Tokushige K; Ono C; Ishibashi T; Vandendries E
    Cancer Sci; 2012 May; 103(5):933-8. PubMed ID: 22335424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
    Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
    Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
    Sullivan-Chang L; O'Donnell RT; Tuscano JM
    BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
    Paul MR; Wong V; Aristizabal P; Kuo DJ
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):e546-e549. PubMed ID: 30807395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Jain N; O'Brien S; Thomas D; Kantarjian H
    Front Biosci (Elite Ed); 2014 Jan; 6(1):40-5. PubMed ID: 24389139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
    Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.